"label","description","uuid:ID","id","name","rationale"
"","The main design for the study","2c8da930-a831-4ef6-b77a-d094b9327ce0","StudyDesign_1","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
